CorMedix Inc.

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.31 ^USD	+2.31%		+0.57%	+41.22%

Apr. 15	CorMedix's DefenCath Now Commercially Available For US Inpatient Use	MT
Apr. 15	CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	CI

CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 12, 2024 at 07:36 am EDT

CorMedix Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 14.75 million compared to USD 8.21 million a year ago.

Latest news about CorMedix Inc.

CorMedix's DefenCath Now Commercially Available For US Inpatient Use	Apr. 15	MT
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	Apr. 15	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization	Apr. 08	MT
CorMedix Inc. Announces Commercial Agreement with ARC Dialysis, LLC	Apr. 08	CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon	Mar. 13	MT
CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says	Mar. 13	MT
RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	Mar. 13	MT
Transcript : CorMedix Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath	Jan. 30	CI
Cormedix Inc. Announces Commercial and Operational Updates	Jan. 08	CI
CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts	Dec. 15	CI
CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023	Dec. 15	CI
CorMedix Inc. Announces Partnership with The Leapfrog Group	Dec. 04	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 15	MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	Nov. 15	MT
Sector Update: Health Care	Nov. 15	MT
CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients	Nov. 15	CI
CorMedix's DefenCath Approved by US FDA; Shares Jump	Nov. 15	MT
U.S. FDA approves CorMedix's antimicrobial drug	Nov. 15	RE
RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk	Nov. 15	MT
CorMedix Q3 Net Loss Steady; Sees Cash Position Sufficient to Fund Operations for 12 Months	Nov. 14	MT

Chart CorMedix Inc.

Duration

Period

More charts

Company Profile

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.31 USD

Average target price

13 USD

Spread / Average Target

+144.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CORMEDIX INC.	+41.22%	292M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals

CorMedix Inc.

Equities

CRMD

US21900C3088

Pharmaceuticals

CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

Latest news about CorMedix Inc.

Chart CorMedix Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals